New investors boost cancer blood-testing firm ’s $257M Series B round

A Cambridge startup developing a blood test to better detect early cancer has raised new venture capital funding as it mulls an early product launch.   Thrive Earlier Detection Corp. raised $257 million in new financing this week. At least 11 new investors, including Bain Capital Life Sciences, contributed to the Series B funding round alongside existing investors. Thrive launched early last year with $110 million in Series A funding, which wa s one of the biggest Series A rounds at the time (a…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news